Statement of Organization, Functions, and Delegations of Authority, 7489-7490 [2010-3069]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–3218 Filed 2–18–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
pwalker on DSK8KYBLC1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Quantitative Imaging for Evaluation of
Responses to Cancer Therapies.
Date: March 4, 2010.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Viatcheslav A
Soldatenkov, M.D., PhD, Scientific Review
Officer, Special Review and Logistics Branch,
Division of Extramural Activities, National
Cancer Institute, 6116 Executive Blvd., Room
8057, Bethesda, MD 20892–8329. 301–451–
4758. soldatenkovv@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR Topic
258.
Date: March 25, 2010.
Time: 12:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6116
Executive Boulevard, Room 210, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Viatcheslav A
Soldatenkov, M.D., PhD, Scientific Review
Officer, Special Review and Logistics Branch,
VerDate Nov<24>2008
18:05 Feb 18, 2010
Jkt 220001
Division of Extramural Activities, National
Cancer Institute, 6116 Executive Blvd., Room
8057, Bethesda, MD 20892–8329. 301–451–
4758. soldatenkovv@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR Topic
276.
Date: March 26, 2010.
Time: 12:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6116
Executive Boulevard, Room 210, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Viatcheslav A
Soldatenkov, M.D., PhD, Scientific Review
Officer, Special Review and Logistics Branch,
Division of Extramural Activities, National
Cancer Institute, 6116 Executive Blvd., Room
8057, Bethesda, MD 20892–8329. 301–451–
4758. soldatenkovv@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Portable eTechnology Diet and Physical Activity Tools
for Consumers.
Date: April 7, 2010.
Time: 11 a.m. to 3 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6116
Executive Boulevard, Room 405, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Marvin L. Salin, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 7073,
Bethesda, MD 20892–8329. 301–496–0694.
msalin@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
7489
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; The Early
Detection Research Network: Clinical
Validation Centers.
Date: March 17, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Legacy Hotel and Meeting Center,
1775 Rockville Pike, Rockville, MD 20852.
Contact Person: Lalita D. Palekar, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 7141, Bethesda,
MD 20892, 301–496–7575,
palekarl@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI Cancer
Nanotechnology Training (R25) and Career
Development Award (K99/R00) Applications.
Date: March 23–24, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Jeannette F Korczak, PhD,
Scientific Review Administrator, Resources
and Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Blvd., Room
8115, Bethesda, MD 20892, 301–496–9767,
korczakj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
BILLING CODE 4140–01–P
Dated: February 4, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2010–3191 Filed 2–18–10; 8:45 am]
[FR Doc. 2010–3189 Filed 2–18–10; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
E:\FR\FM\19FEN1.SGM
19FEN1
7490
Federal Register / Vol. 75, No. 33 / Friday, February 19, 2010 / Notices
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 74 FR 68630–3 1, dated
December 28, 2009) is amended to
reflect the establishment of the Office of
Noncommunicable Diseases, Injury and
Environmental Health.
Section C–B, Organization and
Functions, is hereby amended as
follows:
After the mission statement for the
Centers for Disease Control and
Prevention (C), delete the title and insert
the following:
Office of Noncommunicable Diseases,
Injury and Environmental Health (CU).
The mission of the Office of
Noncommunicable Diseases, Injury and
Environmental Health (ONDIEH) is to
reduce the burden of noncommunicable
diseases, injuries, disabilities and
environmental health hazards.
Office of the Director (CUA). (1)
Advises the CDC Director on issues
related to noncommunicable diseases,
injury prevention, disability, and
environmental health; (2) provides
overall strategic direction and
leadership for noncommunicable
diseases, injury prevention, disability
and environmental health; (3) promotes
and supports noncommunicable
diseases, injury prevention, disability,
and environmental health related
science, policies and programs; and (4)
identifies, facilitates, and promotes
cross center and cross-agency
collaboration, innovation, and new
initiatives related to noncommunicable
diseases, injury prevention, disability,
and environmental health.
Dated: February 3, 2010.
William P. Nichols,
Acting Chief Operating Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2010–3069 Filed 2–18–10; 8:45 am]
BILLING CODE 4160–18–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
pwalker on DSK8KYBLC1PROD with NOTICES
[Docket No. FDA–2009–N–0376]
Office of the Commissioner
Reorganization; Statement of
Organizations, Functions, and
Delegations of Authority
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
VerDate Nov<24>2008
18:05 Feb 18, 2010
Jkt 220001
reorganization of the Office of the
Commissioner (OC). This reorganization
includes the organizations and their
substructure components as listed in
this document. This notice was
previously published in the Federal
Register of August 18, 2009, but it
contained several errors. For the
convenience of the reader, the
reorganization is being published again
in its entirety.
FOR FURTHER INFORMATION CONTACT:
Vanessa Starks, Office of Management
Programs (HFA–400), Food and Drug
Administration, 5600 Fishers Lane, rm.
6B–42, Rockville, MD 20857, 301–827–
1463.
SUPPLEMENTARY INFORMATION: In the
Federal Register of August 18, 2009 (74
FR 41713), FDA published a notice
announcing the reorganization of the
Office of the Commissioner (OC). This
reorganization includes the realignment
of four Deputy-level offices within OC.
They are as follows: (1) The Office of the
Chief Scientist; (2) the Office of
Administration (formerly titled the
Office of Operations); (3) the Office of
Foods; and (4) the Office of Policy,
Planning and Budget (formerly titled the
Office of Policy, Planning and
Preparedness).
Office of Chief of Staff: The Office of
Chief of Staff will advise and provide
integrated policy analysis and strategic
consultation to the Commissioner, the
Principal Deputy Commissioner, Deputy
Commissioners, and other senior FDA
officials on activities and issues that
affect significant agency programs,
projects and initiatives. Often this
function involves the most difficult
problems, crisis situations and
extremely complex issues of the
Agency. This Office will include the
Executive Secretariat Staff. This Office
will report directly to the
Commissioner.
Office of Legislation: The Office of
Legislation will be restructured from the
Office of the Chief of Staff. The Office
of Legislation will report directly to the
Commissioner and have an indirect
reporting relationship to the Deputy
Commissioner for Policy, Planning and
Budget.
Office of Policy, Planning and Budget:
The Office of Policy, Planning and
Budget will be retitled from the Office
of Policy, Planning and Preparedness.
The Office of Policy, Planning and
Budget will be restructured to consist of
the Office of Policy, the Office of
Planning and the Office of Budget
(formerly the Office of Budget
Formulation and Presentation). The
Office of Policy will consist of the
Policy Development and Coordination
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Staff, Regulations Policy and
Management Staff, and Regulations
Editorial Section. The Office of Planning
will consist of the Planning Staff,
Evaluation Staff, Economic Staff, Risk
Communication Staff, and Business
Process Planning Staff. The Office of
Policy, Planning and Budget will report
directly to the Commissioner.
Office of the Counselor to the
Commissioner: The Office of the
Counselor to the Commissioner will be
established to formulate and render
advice to the Commissioner that is
related to policy development,
interpretation, and integration that cuts
across program lines or which is not
well defined. This Office will include
the Office of Crisis Management. The
Office of the Counselor to the
Commissioner will report directly to the
Commissioner.
Office of Women’s Health: The Office
of Women’s Health will be realigned
from the Office of the Chief Scientist,
Office of Science and Health
Coordination. The Office of Women’s
Health will report directly to the
Commissioner.
Office of Special Medical Programs:
The Office of Special Medical Programs
is a newly created Office within OC
with functions and substructure
realigned from components of existing
offices. The Office of Special Medical
Programs will consist of the following
components: Office of Pediatric
Therapeutics, Office of Combination
Products, Office of Orphan Product
Development, and Office of Good
Clinical Practice (formerly titled the
Good Clinical Practice Program) which
all will be realigned from the Office of
the Chief Scientist. The Office of Special
Medical Programs will also include the
Advisory Committee Management and
Oversight Staff (formerly in the Office of
Policy, Planning, and Preparedness).
This Office will report directly to the
Commissioner.
Office of External Affairs: The Office
of External Affairs will be established to
serve as a focal point for improving
FDA’s communications to media,
Congress, and the general public; and to
also advise the Commissioner on better
internal communications within the
Agency. This Office will consist of the
Office of External Relations, the Office
of Public Affairs and the Office of
Special Health Issues. This Office will
report directly to the Commissioner.
Office of Foods: The Office of Foods
will be established to elevate and
empower our food safety activities. This
office, led by the Deputy Commissioner
for Foods, will provide executive
leadership and management to all FDA
food programs, and will be accountable
E:\FR\FM\19FEN1.SGM
19FEN1
]]>Agencies
[Federal Register Volume 75, Number 33 (Friday, February 19, 2010)]
[Notices]
[Pages 7489-7490]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-3069]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and
[[Page 7490]]
Delegations of Authority of the Department of Health and Human Services
(45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296,
October 20, 1980, as amended most recently at 74 FR 68630-3 1, dated
December 28, 2009) is amended to reflect the establishment of the
Office of Noncommunicable Diseases, Injury and Environmental Health.
Section C-B, Organization and Functions, is hereby amended as
follows:
After the mission statement for the Centers for Disease Control and
Prevention (C), delete the title and insert the following:
Office of Noncommunicable Diseases, Injury and Environmental Health
(CU). The mission of the Office of Noncommunicable Diseases, Injury and
Environmental Health (ONDIEH) is to reduce the burden of
noncommunicable diseases, injuries, disabilities and environmental
health hazards.
Office of the Director (CUA). (1) Advises the CDC Director on
issues related to noncommunicable diseases, injury prevention,
disability, and environmental health; (2) provides overall strategic
direction and leadership for noncommunicable diseases, injury
prevention, disability and environmental health; (3) promotes and
supports noncommunicable diseases, injury prevention, disability, and
environmental health related science, policies and programs; and (4)
identifies, facilitates, and promotes cross center and cross-agency
collaboration, innovation, and new initiatives related to
noncommunicable diseases, injury prevention, disability, and
environmental health.
Dated: February 3, 2010.
William P. Nichols,
Acting Chief Operating Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2010-3069 Filed 2-18-10; 8:45 am]
BILLING CODE 4160-18-M
